Neuland Laboratories Limited (NEULANDLAB)

Name: Neuland Laboratories Limited (NEULANDLAB) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-09-20

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Dati chiave

Capitalizzazione di mercato: ₹293 billion
Ricavi (esercizio chiuso a 2026-03-31): ₹19.3B
Utile netto: ₹3.6B
Margine lordo: 51.0%
Margine netto: 18.8%

Vedi grafici interattivi e bilanci completi →

Conto economico annuale

Conto economico	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Entrate totali	₹19.3B	₹14.3B	₹15.2B	₹11.6B
Utile lordo	₹9.8B	₹6.8B	₹7.8B	₹5.5B
Risultato Operativo (EBIT)	₹4.9B	₹2.7B	₹4.1B	₹2.3B
Reddito netto	₹3.6B	₹2.6B	₹3.0B	₹1.6B

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di NEULANDLAB. /companies/us/NEULANDLAB

Aziende simili

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.